Mental Disorder Drugs Market Report 2021-2031
Mental Disorder Drugs Market – reveals latest trends, opportunities, predicted revenues, and competitive analysis. Read on to determine how you can exploit the impending business opportunities emerging in this sector along with detailed COVID-19 recovery scenarios.
Global mental disorder drugs market is projected to reach at a market value of US$xx billion by 2031 with a lucrative CAGR during the forecast period. The growing prevalence of mental disorders including depression, bipolar disorder, anxiety, and schizophrenia is a major factor that drives the demand for mental disorder drugs. Other key drivers boosting the market growth are growing mental health awareness in developing countries; adoption of mental disorder drugs for treatment & maintenance therapy; and rising R&D investment by the leading pharmaceutical companies in the area of mental health. In addition, the COVID-19 pandemic has a significant impact on the mental disorder drugs market. The COVID-19 pandemic has resulted in a growing incidence of mental disorders due to unemployment, financial crisis, health issues, and stress. Thus, the demand for mental disorder drugs is expected to rise during the forecast period.
Visiongain’s report shows you the potential revenues streams to 2031, assessing the different segments, major players, qualitative analysis, opportunities trends, and business prospects in the mental disorder drugs industry.
How this report will benefit you
Visiongain’s new study is envisioned for anyone requiring commercial in-depth analyses for the global mental disorder drugs market along with detailed segment analysis in the market. Our new study assists you to evaluate the overall global and regional market for mental disorder drugs. Get the financial analysis of the overall market and different segments including by drug class, route of administration, usability, and distribution channel. High opportunity remains in this fast-growing mental disorder drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefit in the near future. Moreover, the report would help you to improve your strategic decision making, allows you to frame growth strategies, reinforce the analysis of other market players, and maximise productivity of the company.
Forecasts to 2031 and other analyses reveal the commercial prospects
- Our new study provides you with revenue forecast by different segments including drug class, indication, and distribution channel to 2031
- It also includes growth rates for different 5 regional markets along with 18 countries and COVID-19 impact analysis on each market
- The profiles of the top 15 companies are very descriptive and comprehensive data including company snapshot, overview, commercial developments, company market shares, and detailed financial analysis with revenue and other financials
- The COVID-19 has a positive impact on the mental disorder drugs industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry.
Along with revenue prediction for the overall global market, there is segmentation by region for 5 regional markets including North America, Europe, Asia Pacific, Latin America, and MEA and 20 major countries.
Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Drug Class
- SSRIs
- SNRIs
- Atypical Antipsychotics
- TCAs
- SARIs
- Benzodiazepines
- MAOIs
- Others
- Depression
- Schizophrenia
- Bipolar disorder
- Post-traumatic Stress Disorder
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Detailed profiles of 15 leading companies that are operating in the market
The report includes profiles of 15 major companies involved in the mental disorder drugs market. The companies profiled in this report include: AbbVie, AstraZeneca, Bausch Health, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck, Novartis, Otsuka Pharmaceutical, Pfizer, Takeda Pharmaceutical, and Teva Pharmaceutical Industries.
Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
In summary, our 429-page report delivers you with the following knowledge:
- Revenue forecasts from 2021 to 2031 for the global mental disorder drugs market and subsegments (by drug class, indication, distribution channel, and region)– discover the industry’s prospects, finding the most lucrative areas for investments and revenue generation
- Detailed profiles of top 15 mental disorder drugs manufacturers, with financial overviews for net revenues, operating income, R&D investment, and segment revenues
- Revenue forecasts from 2021 to 2031 for 5 regional markets – See forecasts for the mental disorder drugs market in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the mental disorder drugs market and detailed analysis of COVID-19 impact. You will get the most recent data, opportunities, trends, and predictions.
The Mental Disorder Drugs Market Forecast 2021-2031 will be of value to anyone who wants to better understand the market and its various segments. It would be valuable for companies that desire to better understand the part of the industry they are involved in, or those coveting to expand or enter into a different regional market or to understand strategic analysis of leading companies of the mental disorder drugs industry.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1 Introduction to Mental Disorder Drugs Market
- 1.1.1 What Is Mental Disorder?
- 1.1.2 Types of Mental Disorders
- 1.1.3 Prevalence and Mortality for Mental Disorders
- 1.2 Why You Should Read This Report
- 1.3 What This Report Delivers
- 1.4 Key Questions Answered By This Analytical Report Include:
- 1.5 Who is This Report For?
- 1.6 Methodology
- 1.6.1 Primary Research
- 1.6.2 Secondary Research
- 1.6.3 Market Evaluation & Forecast Methodology
- 1.7 Frequently Asked Questions (FAQs)
- 1.8 Associated Visiongain Reports
- 1.9 About Visiongain
- 2 Executive Summary
- 3 Market Dynamics
- 3.1 Drivers
- 3.1.1 Development of Advanced Mental Disorder Drugs
- 3.1.2 Increasing Prevalence of Mental Disorders
- 3.1.3 Escalating of Mental Healthcare Awareness
- 3.2 Restraints
- 3.2.1 Increasing Development of Novel Drugs
- 3.2.2 Social Stigma of Mental Disorders
- 3.2.3 Stringent Regulatory Guidelines for New Drug Approval
- 3.3 Opportunities
- 3.3.1 Growing Demand for Cutting-Edge Therapeutic Treatments for Mental Disorders to Aid Market Growth
- 3.3.2 Increase in Geriatric Population
- 3.4 Trends
- 3.4.1 Mergers, Agreements, and Acquisitions by the Market Players
- 3.4.2 Expected Launch of New Drugs is Expected to Drive the Market Growth
- 3.5 SWOT Analysis
- 3.5.1 Strengths: The Most Dynamic Area of the Mental Disorders Market
- 3.5.2 Weaknesses
- 3.5.3 Opportunities
- 3.5.3.1 Increasing Mergers & Acquisitions and Collaborations
- 3.5.3.2 Large Amount of R&D Investment
- 3.5.4 Threats
- 3.6 Porter’s Five Forces Analysis
- 3.6.1 Bargaining Power of Supplier: Moderate
- 3.6.2 Bargaining Power of Buyer: Moderate
- 3.6.3 Competitive Rivalry: High
- 3.6.4 Threat of New Entrants: Moderate
- 3.6.5 Threat of Substitutes: Moderate
- 3.7 PEST Analysis
- 3.7.1 Political Factors Impacting Mental Disorder Drugs Market
- 3.7.2 Economic Factors Impacting Mental Disorder Drugs Market
- 3.7.3 Social Factors Impacting Mental Disorder Drugs Market
- 3.7.4 Technological Factors Impacting Mental Disorder Drugs Market
- 4 Global Mental Disorder Drugs Market Forecast, 2021-2031
- 4.1 Global Mental Disorder Drugs Market Forecast 2021-2031
- 5 COVID-19 Impact: Global Mental Disorder Drugs Market
- 5.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
- 5.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
- 5.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
- 5.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth
- 6 Global Mental Disorder Drugs Market Size Forecast 2021-2031 by Drug Class
- 6.1 Global SSRIs Segment: Revenue Forecast 2021-2031
- 6.1.1 Largest Revenue Grossing Segment
- 6.1.2 Recovery Forecasts (V, U, W, L)
- 6.2 Global SNRIs Segment: Revenue Forecast 2021-2031
- 6.2.1 Increase in Adoption of These Drugs for the Treatment of Mental Disorders
- 6.2.2 Recovery Forecasts (V, U, W, L)
- 6.3 Global Atypical Antipsychotics Segment: Revenue Forecast 2021-2031
- 6.3.1 Atypical Antipsychotics Segment is Expected to Grow at a Lucrative Growth Rate
- 6.3.2 Recovery Forecasts (V, U, W, L)
- 6.4 Global TCAs Segment: Revenue Forecast 2021-2031
- 6.4.1 TCAs Play an In the Treatment of Severe Depression
- 6.4.2 Recovery Forecasts (V, U, W, L)
- 6.5 Global SARIs Segment: Revenue Forecast 2021-2031
- 6.5.1 SARIs Are Mainly Used For The Treatment MDD
- 6.5.2 Recovery Forecasts (V, U, W, L)
- 6.6 Global Benzodiazepines Segment: Revenue Forecast 2021-2031
- 6.6.1 Benzodiazepines Segment is Presumed to Witness Moderate Growth over the Forecast Period
- 6.6.2 Recovery Forecasts (V, U, W, L)
- 6.7 Global MAOIs Segment: Revenue Forecast 2021-2031
- 6.7.1 MAOIs Segment Expected To Witness Lucrative CAGR during the Forecast Period
- 6.7.2 Recovery Forecasts (V, U, W, L)
- 6.8 Global Others Segment: Revenue Forecast 2021-2031
- 6.8.1 Growing Demand for Advanced Drugs Is Expected to Propel the Segment Growth
- 6.8.2 Recovery Forecasts (V, U, W, L)
- 7 Global Mental Disorder Drugs Market Size Forecast 2021-2031 by Indication
- 7.1 Global Depression Segment: Revenue Forecast 2021-2031
- 7.1.1 Largest Revenue Grossing Segment
- 7.1.2 Recovery Forecasts (V, U, W, L)
- 7.2 Global Schizophrenia Segment: Revenue Forecast 2021-2031
- 7.2.1 Mounting Prevalence of Schizophrenia Worldwide Will Drive the Segment Growth
- 7.2.2 Recovery Forecasts (V, U, W, L)
- 7.3 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031
- 7.3.1 Adoption of Generic Drugs for the Treatment of Bipolar Disorder
- 7.3.2 Recovery Forecasts (V, U, W, L)
- 7.4 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031
- 7.4.1 Growing R&D expenditure in the development of therapeutically advanced mental disorder drugs
- 7.4.2 Recovery Forecasts (V, U, W, L)
- 7.5 Global Others Segment: Revenue Forecast 2021-2031
- 7.5.1 Rising Prevalence of Other Mental Disorders
- 7.5.2 Recovery Forecasts (V, U, W, L)
- 8 Mental Disorder Drugs Market by Distribution Channel Forecast, 2021-2031
- 8.1 Hospital Pharmacy Segment Market Forecast, 2021-2031
- 8.1.1 Largest Revenue Generating Segment
- 8.1.2 Recovery Scenarios (V, U, W, L)
- 8.2 Retail Pharmacy Segment Market Forecast, 2021-2031
- 8.2.1 Fastest Growing Segment in the Market
- 8.2.2 Recovery Scenarios (V, U, W, L)
- 8.3 Others Segment Market Forecast, 2021-2031
- 8.3.1 Developing Healthcare Infrastructure Is Expected To Drive the Market Growth
- 8.3.2 Recovery Scenarios (V, U, W, L)
- 9 Global Mental Disorder Drugs Market Forecast, 2021-2031
- 9.1 Global Mental Disorder Drugs Market by Region Forecast 2021-2031
- 9.2 Recovery Scenarios (V, U, W, L)
- 10 North America Mental Disorder Drugs Market, 2021-2031
- 10.1 North America is The Largest Revenue Grossing Region in the Global Market
- 10.2 North America Mental Disorder Drugs Market by Country, Forecast 2021-2031
- 10.3 Recovery Scenarios (V, U, W, L)
- 10.4 North America Mental Disorder Drugs Market Forecast by Drug Class
- 10.5 North America Mental Disorder Drugs Market Forecast by Indication
- 10.6 North America Mental Disorder Drugs Market Forecast by Distribution Channel
- 10.7 U.S. Mental Disorder Drugs Market Forecast, 2021-2031
- 10.7.1 Rise in the Number of Drug Approvals
- 10.7.2 Presence of Highly Developed Healthcare Infrastructure
- 10.7.3 Recovery Scenarios (V, U, W, L): U.S. Mental Disorder Drugs Market Forecast, 2021-2031
- 10.8 Canada Mental Disorder Drugs Market Forecast, 2021-2031
- 10.8.1 Anticipated To Witness the Fastest Growth in the North America Region
- 10.8.2 Benefits of Manufacturing and R&D Operations in Canada
- 10.8.3 Recovery Scenarios (V, U, W, L): Canada Mental Disorder Drugs Market Forecast, 2021-2031
- 11 Europe Mental Disorder Drugs Market, 2021-2031
- 11.1 Second Largest Market in the Global Market
- 11.2 Europe Mental Disorder Drugs Market by Country, Forecast 2021-2031
- 11.3 Recovery Scenarios (V, U, W, L)
- 11.4 Europe Mental Disorder Drugs Market Forecast by Drug Class
- 11.5 Europe Mental Disorder Drugs Market Forecast by Indication
- 11.6 Europe Mental Disorder Drugs Market Forecast by Distribution Channel
- 11.7 Germany Mental Disorder Drugs Market Forecast, 2021-2031
- 11.7.1 Growing Geriatric Population In This Region Is Expected To Boost The Regional Market Growth
- 11.7.2 One of the Oldest Universal Health Systems within Europe
- 11.7.3 Recovery Scenarios (V, U, W, L): Germany Mental Disorder Drugs Market Forecast, 2021-2031
- 11.8 UK Mental Disorder Drugs Market Forecast, 2021-2031
- 11.8.1 Presence of Well-Developed R&D Infrastructure
- 11.8.2 Increasing Prevalence of Mental Disorders in This Region
- 11.8.3 Recovery Scenarios (V, U, W, L): UK Mental Disorder Drugs Market Forecast, 2021-2031
- 11.9 France Mental Disorder Drugs Market Forecast, 2021-2031
- 11.9.1 Growing Demand For Affordable Healthcare Services
- 11.9.2 Growing Demand for Innovative Medicine and Pharmaceutical
- 11.9.3 Recovery Scenarios (V, U, W, L): France Mental Disorder Drugs Market Forecast, 2021-2031
- 11.10 Italy Mental Disorder Drugs Market Forecast, 2021-2031
- 11.10.1 Pharmaceutical Manufacturing Hub
- 11.10.2 Growing Demand for Advanced Therapies for the Treatment of Mental Disorders
- 11.10.3 Recovery Scenarios (V, U, W, L): Italy Mental Disorder Drugs Market Forecast, 2021-2031
- 11.11 Spain Mental Disorder Drugs Market Forecast, 2021-2031
- 11.11.1 Spanish Economy Is Growing Strong
- 11.11.2 Demand for Drugs Is Influenced By the Growth of the Pharmaceutical Industry
- 11.11.3 Recovery Scenarios (V, U, W, L): Spain Mental Disorder Drugs Market Forecast, 2021-2031
- 11.12 Russia Mental Disorder Drugs Market Forecast, 2021-2031
- 11.12.1 Unmet Pharmaceutical Needs
- 11.12.2 Government Support For Development of the Healthcare Infrastructure
- 11.12.3 Recovery Scenarios (V, U, W, L): Russia Mental Disorder Drugs Market Forecast, 2021-2031
- 11.13 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031
- 11.13.1 Increasing Prevalence of Mental Disorders
- 11.13.2 Recovery Scenarios (V, U, W, L): Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031
- 12 Asia Pacific Mental Disorder Drugs Market, 2021-2031
- 12.1 Asia Pacific is the Fastest Growing Market
- 12.2 Asia Pacific Mental Disorder Drugs Market by Country, Forecast 2021-2031
- 12.3 Recovery Scenarios (V, U, W, L)
- 12.4 Asia Pacific Mental Disorder Drugs Market Forecast by Drug Class
- 12.5 Asia Pacific Mental Disorder Drugs Market Forecast by Indication
- 12.6 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel
- 12.7 Japan Mental Disorder Drugs Market Forecast, 2021-2031
- 12.7.1 Japan Accounted For the Largest Market Share in the Asia Pacific Region
- 12.7.2 Government Initiatives
- 12.7.3 Recovery Scenarios (V, U, W, L): Japan Mental Disorder Drugs Market Forecast, 2021-2031
- 12.8 China Mental Disorder Drugs Market Forecast, 2021-2031
- 12.8.1 Presence of Large Geriatric Population
- 12.8.2 Increasing Healthcare Spending In China
- 12.8.3 Recovery Scenarios (V, U, W, L): China Mental Disorder Drugs Market Forecast, 2021-2031
- 12.9 India Mental Disorder Drugs Market Forecast, 2021-2031
- 12.9.1 Developing Healthcare Infrastructure
- 12.9.2 Increasing Prevalence of Mental Disorders
- 12.9.3 Recovery Scenarios (V, U, W, L): India Mental Disorder Drugs Market Forecast, 2021-2031
- 12.10 Australia Mental Disorder Drugs Market Forecast, 2021-2031
- 12.10.1 Government Programs to Expand Access to Quality Eye Care Facilities
- 12.10.2 Well Established Healthcare Infrastructure
- 12.10.3 Recovery Scenarios (V, U, W, L): Australia Mental Disorder Drugs Market Forecast, 2021-2031
- 12.11 South Korea Mental Disorder Drugs Market Forecast, 2021-2031
- 12.11.1 Growing Healthcare Awareness among People
- 12.11.2 Increasing Prevalence of Depression
- 12.11.3 Recovery Scenarios (V, U, W, L): South Korea Mental Disorder Drugs Market Forecast, 2021-2031
- 12.12 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031
- 12.12.1 Rising Disposable Income
- 12.12.2 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031
- 13 Latin America Mental Disorder Drugs Market, 2021-2031
- 13.1 Latin America Mental Disorder Drugs Market
- 13.2 Latin America Mental Disorder Drugs Market by Country, Forecast 2021-2031
- 13.3 Recovery Scenarios (V, U, W, L)
- 13.4 Latin America Mental Disorder Drugs Market Forecast by Drug Class
- 13.5 Latin America Mental Disorder Drugs Market Forecast by Indication
- 13.6 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel
- 13.7 Brazil Mental Disorder Drugs Market Forecast, 2021-2031
- 13.7.1 Fastest Growing Economies in Latin America
- 13.7.2 Government Incentives to Keep Manufacturing Local
- 13.7.3 Recovery Scenarios (V, U, W, L): Brazil Mental Disorder Drugs Market Forecast, 2021-2031
- 13.8 Mexico Mental Disorder Drugs Market Forecast, 2021-2031
- 13.8.1 Lower Manufacturing Costs than In the US
- 13.8.2 Favourable Initiatives Undertaken By Private and Public Sectors
- 13.8.3 Recovery Scenarios (V, U, W, L): Mexico Mental Disorder Drugs Market Forecast, 2021-2031
- 13.9 Argentina Mental Disorder Drugs Market Forecast, 2021-2031
- 13.9.1 Boom in Pharmaceutical Industry
- 13.9.2 Adoption of Depression and Other Mental Disorders Drugs
- 13.9.3 Recovery Scenarios (V, U, W, L): Argentina Mental Disorder Drugs Market Forecast, 2021-2031
- 13.10 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031
- 13.10.1 Developing Healthcare Infrastructure
- 13.10.2 Recovery Scenarios (V, U, W, L): Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031
- 14 MEA Mental Disorder Drugs Market, 2021-2031
- 14.1 Rising Prevalence of Mental Disorders
- 14.2 MEA Mental Disorder Drugs Market by Country, Forecast 2021-2031
- 14.3 Recovery Scenarios (V, U, W, L)
- 14.4 MEA Mental Disorder Drugs Market Forecast by Drug Class
- 14.5 MEA Mental Disorder Drugs Market Forecast by Indication
- 14.6 MEA Mental Disorder Drugs Market Forecast by Distribution Channel
- 14.7 South Africa Mental Disorder Drugs Market Forecast, 2021-2031
- 14.7.1 Increasing Focus of Pharmaceutical & Pharmaceutical Companies in This Region
- 14.7.2 Supportive Government Initiatives
- 14.7.3 Recovery Scenarios (V, U, W, L): South Africa Mental Disorder Drugs Market Forecast, 2021-2031
- 14.8 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031
- 14.8.1 Presence of Huge Growth Opportunities
- 14.8.2 Presence of Huge Growth Opportunities
- 14.8.3 Recovery Scenarios (V, U, W, L): Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031
- 14.9 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031
- 14.9.1 Strong Presence Of Leading Companies
- 14.9.2 Growing Prevalence of Mental Disorders
- 14.9.3 Recovery Scenarios (V, U, W, L): Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031
- 15 Company Profiles
- 15.1 Company Share Analysis
- 15.2 Mental Disorder Drugs Market Recent Developments, 2017-2020
- 15.3 Novartis AG
- 15.3.1 Company Snapshot
- 15.3.2 Company Overview
- 15.3.3 Financial Analysis
- 15.3.3.1 Net Revenue, 2015-2019
- 15.3.3.2 Product Revenue Shares, 2019
- 15.3.3.3 Novartis Pharmaceuticals Business Unit Revenue Shares, 2019
- 15.3.3.4 Regional Revenue Shares, 2019
- 15.3.4 Product Benchmarking
- 15.3.5 Recent Developments, 2017-2020
- 15.4 GlaxoSmithKline Pharmaceuticals Ltd.
- 15.4.1 Company Snapshot
- 15.4.2 Company Overview
- 15.4.3 Financial Analysis
- 15.4.3.1 Net Revenue, 2015-2019
- 15.4.3.2 Product Revenue Shares, 2019
- 15.4.3.3 Pharmaceuticals Segment Revenue Shares, 2019
- 15.4.3.4 Regional Revenue Shares, 2019
- 15.4.4 Product Benchmarking
- 15.4.5 Recent Developments, 2017-2020
- 15.5 Pfizer Inc.
- 15.5.1 Company Snapshot
- 15.5.2 Company Overview
- 15.5.3 Financial Analysis
- 15.5.3.1 Net Revenue, 2015-2019
- 15.5.3.2 Product Revenue Shares, 2019
- 15.5.3.3 Regional Revenue Shares, 2019
- 15.5.4 Product Benchmarking
- 15.5.5 Recent Developments, 2017-2020
- 15.6 AbbVie Inc.
- 15.6.1 Company Snapshot
- 15.6.2 Company Overview
- 15.6.3 Financial Analysis
- 15.6.3.1 Net Revenue, 2015-2019
- 15.6.3.2 Product Revenue Shares, 2019
- 15.6.3.3 Regional Revenue Shares, 2019
- 15.6.4 Product Benchmarking
- 15.6.5 Recent Developments, 2017-2020
- 15.7 Johnson & Johnson
- 15.7.1 Company Snapshot
- 15.7.2 Company Overview
- 15.7.3 Financial Analysis
- 15.7.3.1 Net Revenue, 2015-2019
- 15.7.3.2 Product Revenue Shares, 2019
- 15.7.3.3 Regional Revenue Shares, 2019
- 15.7.4 Product Benchmarking
- 15.7.5 Recent Developments, 2017-2020
- 15.8 AstraZeneca
- 15.8.1 Company Snapshot
- 15.8.2 Company Overview
- 15.8.3 Financial Analysis
- 15.8.3.1 Net Revenue, 2015-2019
- 15.8.3.2 Product Revenue Shares, 2019
- 15.8.3.3 Regional Revenue Shares, 2019
- 15.8.4 Product Benchmarking
- 15.8.5 Recent Developments, 2017-2020
- 15.9 Otsuka Pharmaceuticals
- 15.9.1 Company Snapshot
- 15.9.2 Company Overview
- 15.9.3 Product Benchmarking
- 15.9.4 Recent Developments, 2017-2020
- 15.10 Eli Lilly and Company
- 15.10.1 Company Snapshot
- 15.10.2 Company Overview
- 15.10.3 Financial Analysis
- 15.10.3.1 Net Revenue, 2015-2019
- 15.10.3.2 Product Revenue Shares, 2019
- 15.10.3.3 Regional Revenue Shares, 2019
- 15.10.4 Product Benchmarking
- 15.10.5 Recent Developments, 2017-2020
- 15.11 H. Lundbeck A/S
- 15.11.1 Company Snapshot
- 15.11.2 Company Overview
- 15.11.3 Financial Analysis
- 15.11.3.1 Net Revenue, 2015-2019
- 15.11.3.2 Regional Revenue Shares, 2019
- 15.11.4 Product Benchmarking
- 15.11.5 Recent Developments, 2017-2020
- 15.12 Takeda Pharmaceutical Company Ltd.
- 15.12.1 Company Snapshot
- 15.12.2 Company Overview
- 15.12.3 Financial Analysis
- 15.12.3.1 Net Revenue, 2015-2019
- 15.12.3.2 Regional Revenue Shares, 2019
- 15.12.4 Product Benchmarking
- 15.12.5 Recent Developments, 2017-2020
- 15.13 Bausch Health
- 15.13.1 Company Snapshot
- 15.13.2 Company Overview
- 15.13.3 Financial Analysis
- 15.13.3.1 Net Revenue, 2015-2019
- 15.13.3.2 Product Revenue Shares, 2019
- 15.13.3.3 Regional Revenue Shares, 2019
- 15.13.4 Product Benchmarking
- 15.14 Mallinckrodt Pharmaceuticals
- 15.14.1 Company Snapshot
- 15.14.2 Company Overview
- 15.14.3 Financial Analysis
- 15.14.3.1 Net Revenue, 2015-2019
- 15.14.3.2 Product Revenue Shares, 2019
- 15.14.3.3 Regional Revenue Shares, 2019
- 15.14.4 Product Benchmarking
- 15.15 Teva Pharmaceutical Industries Ltd.
- 15.15.1 Company Snapshot
- 15.15.2 Company Overview
- 15.15.3 Financial Analysis
- 15.15.3.1 Net Revenue, 2015-2019
- 15.15.3.2 Product Revenue Shares, 2019
- 15.15.3.3 Regional Revenue Shares, 2019
- 15.15.4 Product Benchmarking
- 15.15.5 Recent Developments, 2017-2020
- 15.16 Merck & Co., Inc.
- 15.16.1 Company Snapshot
- 15.16.2 Company Overview
- 15.16.3 Financial Analysis
- 15.16.3.1 Net Revenue, 2015-2019
- 15.16.3.2 Product Revenue Shares, 2019
- 15.16.3.3 Regional Revenue Shares, 2019
- 15.16.4 Product Benchmarking
- 15.17 Bristol-Myers Squibb
- 15.17.1 Company Snapshot
- 15.17.2 Company Overview
- 15.17.3 Financial Analysis
- 15.17.3.1 Net Revenue, 2015-2019
- 15.17.3.2 Regional Revenue Shares, 2019
- 15.17.4 Product Benchmarking
- 15.17.5 Recent Developments, 2017-2020
- 16 Conclusion and Recommendations
- 16.1 Conclusion
- 16.2 Recommendations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook